Last reviewed · How we verify
QL2109 or Daratumumab — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
QL2109 or Daratumumab (QL2109 or Daratumumab) — Qilu Pharmaceutical Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| QL2109 or Daratumumab TARGET | QL2109 or Daratumumab | Qilu Pharmaceutical Co., Ltd. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- QL2109 or Daratumumab CI watch — RSS
- QL2109 or Daratumumab CI watch — Atom
- QL2109 or Daratumumab CI watch — JSON
- QL2109 or Daratumumab alone — RSS
Cite this brief
Drug Landscape (2026). QL2109 or Daratumumab — Competitive Intelligence Brief. https://druglandscape.com/ci/ql2109-or-daratumumab. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab